## AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

## LISTING OF CLAIMS:

- 1. (currently amended) A formulation comprising:
- pure Saligenin or saligenin-enriched or 100 to 500 mg
  of Salix rubra extract containing 25% by weight of saligenin-or
  acetic or butyric ester of saligenin;
- substantially pure boswellic acid or a pharmaceutically acceptable salt or ester thereof or a boswellic acid enriched 20 to 200 mg of Boswellia serrata extract;
- 50 to 150 mg procyanidins from Vitis vinifera or from Camellia sinensis optionally complexed with phospholipids or rhein;
  - 10 to 500 mg N-acetyl-glucosamine; and
  - 10 to 500 mg of glucuronic acid or glucuronolactone.
- 2. (currently amended) The formulation as claimed in claim 1 comprising:
- \_\_\_\_\_ wherein said Boswellia serrata extract containing contains 20% of boswellic acid;

Docket No. 2503-1186 Appln. No. 10/562,205

- N acetyl glucosamine; and
- glucuronic acid or glucuronolactone.
- 3. (previously presented) The formulation as claimed in claim 1 wherein the *Salix rubra* extract, the *Boswellia serrata* extract, procyanidins, N-acetyl-glucosamine, and glucuronic acid or glucuronolactone are present in 2:1:1:1 weight ratios, respectively.
  - 4. (canceled)
- 5. (previously presented) The formulation as claimed in claim 1 in the form of capsules containing *Enothera biennis* oil as the carrier.
  - 6. (canceled)
- 7. (previously presented) The formulation as claimed in claim 2 in the form of capsules containing *Enothera biennis* oil as the carrier.

Docket No. 2503-1186 Appln. No. 10/562,205

- 8. (previously presented) A formulation as claimed in claim 3 in the form of capsules containing *Enothera biennis* oil as the carrier.
  - 9. (canceled)